COR2ED - Oncology Medical Conversation

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor. Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for adv...

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of Graz, Austria, discuss the role of VEGFR-TKIs in the treatment of advanced renal cell carcinoma (RCC) alone or in combination with immunotherapy. In this podcast, by COR2ED Medical Education, the two experts discuss key trials (CHECKMATE 214, KEYNOTE 426...

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer. In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment...

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer. This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer –...

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer. In this first episode the experts discuss novel targeted approaches in metastatic colorectal and gastric cancer. They discuss...

In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London, UK) and Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine and the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York,...

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment of unresectable or advanced HCC in the first-line setting. They will go into details about who can benefit from monotherapy and will share the current guidance on the implementation of the dosing strategies for the management of toxicity in the clinical practic...

In this medical education podcast series, myeloma experts Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine and the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, USA) and Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London...

Professor Matthias Pinter, medical hepatologist from the medical University of Vienna in Austria shares some insights from key abstracts and topics discussed at ILCA 2021 and ESMO 2021 in hepatocellular carcinoma. One main topic included discussions about treatment options in first-line systemic therapy and managing patients who still may need to receive a TKI in first-line instead. Another topic...

In this podcast, PO CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguarda Cancer Centre, Milan, Italy) provide both a pathologist and medical oncologist perspective about the detection and treatment of TRK fusion-positive GI cancers, with a particular focus on colorectal cancer. Penault-Llorca and Sartore-Bianchi start by...

In this podcast, Veerle Lamotte, an oncology nurse practitioner at Antwerp University Hospital and Paola Belardi, nurse chief at San Donato Hospital in Arezzo, Italy discuss the role of the nurse in the management of adverse events in patients receiving VEGFR-TKI treatment. Their discussion focuses specifically on patients with hepatocellular cancer (HCC), differentiated thyroid cancer and advance...

Dr. Jaume Capdevila, a Medical Oncologist at Vall d’Hebron University Hospital in Barcelona, Spain, and Dr. Rachel van Leeuwaarde, an Endocrinologist from the University Medical Center of Utrecht in The Netherlands discuss the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC). In this podcast, the two...

In this episode, Dr Choo discusses some key abstracts presented during the virtual ASCO and WCGIC congresses in 2021. Dr Choo comments that despite the promising and positive data with hepatic arterial infusion chemotherapy (HAIC) in two different Phase 3 trials settings, the impact on clinical practice is still questionable. Dr Choo reviews some updated data from IMbrave150 which is the study tha...

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer . This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safe...

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer . They are also joined by guest speaker Dr. Neal Shore (Carolina Urologic Research Center, North Carolina, USA). In this first episode, the experts focu...